Sickle Cell Disease Pipeline Summary

DelveInsight’s, “Sickle Cell Disease - Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Sickle Cell Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sickle Cell Disease: Understanding

Sickle Cell Disease: Overview

Sickle cell disease (SCD) is an inherited, multisystem blood disorder caused by abnormal hemoglobin production and is characterized by chronic hemolytic anemia, recurrent vaso-occlusive episodes, progressive organ damage and reduced life expectancy. It encompasses several genotypes, including HbSS, HbSC and HbS/?-thalassemia, with severity varying between individuals. SCD is caused by mutations affecting the ?-globin gene, resulting in production of sickle hemoglobin (HbS). The disease can affect virtually any organ through chronic anemia, vascular injury and impaired blood flow.

Clinical manifestations commonly include recurrent episodes of severe pain, chronic fatigue, pallor, jaundice and anemia resulting from accelerated red-cell destruction. Patients may also develop acute chest syndrome, stroke, infections, splenic dysfunction, priapism, leg ulcers, renal complications and pulmonary hypertension. Vaso-occlusive crises can be triggered or worsened by dehydration, infection, hypoxia, cold exposure or physical stress. Chronic disease may progressively impair multiple organs and substantially affect quality of life and daily functioning.

SCD is inherited in an autosomal recessive manner and results primarily from a point mutation in the ?-globin gene that replaces glutamic acid with valine at position six of the ?-globin chain. Under low-oxygen conditions, HbS molecules polymerize inside red blood cells, causing them to become rigid and adopt the characteristic sickle shape. These poorly deformable cells undergo premature hemolysis and can adhere to vascular endothelium and other blood cells, producing microvascular obstruction, tissue ischemia and inflammation. Repeated vaso-occlusion and hemolysis ultimately contribute to endothelial dysfunction, vasculopathy and progressive organ injury.

Diagnosis is generally established through laboratory testing that identifies abnormal hemoglobin, including newborn screening, hemoglobin electrophoresis, high-performance liquid chromatography or molecular genetic testing when required. Treatment aims to prevent complications, reduce vaso-occlusive episodes and manage chronic anemia and organ damage. Disease-modifying approaches include hydroxyurea, which increases fetal hemoglobin and reduces sickling, while transfusions may be used for selected complications; supportive care includes vaccination, infection prevention, hydration and pain management. Hematopoietic stem-cell transplantation and newer gene therapies can potentially provide a curative or functionally curative approach in appropriately selected patients.

“Sickle Cell Disease - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Sickle Cell Disease pipeline landscape is provided which includes the disease overview and Sickle Cell Disease treatment guidelines. The assessment part of the report embraces, in depth Sickle Cell Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sickle Cell Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sickle Cell Disease R&D. The therapies under development are focused on novel approaches to treat/improve Sickle Cell Disease.

Sickle Cell Disease Emerging Drugs Chapters

This segment of the Sickle Cell Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sickle Cell Disease Emerging Drugs

Etavopivat: Novo Nordisk

Etavopivat is an investigational, once-daily oral pyruvate kinase-R (PKR) activator developed by Novo Nordisk for sickle cell disease (SCD). By activating PKR in red blood cells, it increases ATP and lowers 2,3-DPG, improving red-cell health and reducing hemoglobin S polymerization and sickling. The global Phase III HIBISCUS 2 study is evaluating etavopivat 400 mg versus placebo in adolescents and adults with SCD, with vaso-occlusive crises as the primary endpoint. The earlier Phase III HIBISCUS trial met both co-primary endpoints, showing a 27% reduction in vaso-occlusive crises and improved hemoglobin response; Novo Nordisk plans its first regulatory submission in H2 2026.

SIL-8301: Biossil Inc.

SIL-8301 (senicapoc) is an investigational oral drug being developed by Biossil Inc. for the chronic treatment of sickle cell disease (SCD), particularly patients with a predominantly hemolytic phenotype. It is a Gardos channel inhibitor designed to reduce red blood cell dehydration and thereby decrease hemolysis, with the potential to improve hemoglobin levels and reduce hemolytic complications. In the current Phase II RESCUE study, SIL-8301 is being evaluated against placebo in patients receiving hydroxyurea who have hemoglobin ?9 g/dL and a history of hemolytic complications. The study administers 20 mg twice daily for four days followed by 10 mg once daily for up to 24 weeks, with hemoglobin response and hemolytic markers among the key efficacy measures.

Nulabeglogene autogedtemcel: Kamau Therapeutics

Nulabeglogene autogedtemcel (nula-cel) is an investigational autologous gene-edited hematopoietic stem cell therapy being developed by Kamau Therapeutics for sickle cell disease (SCD). The therapy is designed to correct the underlying sickle-cell mutation in a patient’s own blood-forming stem cells, with the goal of restoring production of functional adult hemoglobin. It is being evaluated in the RESTORE clinical trial in patients with SCD, with the study assessing safety and the potential for durable correction of the disease. The program is currently in Phase I/II development, representing a potentially disease-modifying approach that aims to address the genetic cause of SCD rather than primarily managing its symptoms.

CS-206: CorrectSequence Therapeutics

CS-206 is an investigational autologous gene-edited hematopoietic stem-cell therapy being developed by CorrectSequence Therapeutics Co., Ltd. for severe sickle cell disease. The therapy uses ex vivo base editing to modify the BCL11A-binding site in the HBG promoter, thereby reactivating ?-globin production and increasing fetal hemoglobin (HbF). By increasing HbF, CS-206 aims to compensate for defective adult hemoglobin and reduce sickling-related complications, including vaso-occlusive crises. It is currently being evaluated in a early Phase I study in patients with severe SCD.

Further product details are provided in the report……..

Sickle Cell Disease: Therapeutic Assessment

This segment of the report provides insights about the different Sickle Cell Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Sickle Cell Disease

There are approx. 45+ key companies which are developing the therapies for Sickle Cell Disease. The companies which have their Sickle Cell Disease drug candidates in the most advanced stage, i.e. Phase III include Novo Nordisk.

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Sickle Cell Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sickle Cell Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sickle Cell Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sickle Cell Disease drugs.

Sickle Cell Disease Report Insights

• Sickle Cell Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sickle Cell Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sickle Cell Disease drugs?
• How many Sickle Cell Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sickle Cell Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sickle Cell Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sickle Cell Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novo Nordisk
• Biossil Inc.
• Kamau Therapeutics
• Novartis
• CorrectSequence Therapeutics
• Disc Medicine, Inc
• CSL Behring
• Sanofi
• Bristol-Myers Squibb
• Beam Therapeutics Inc.
• MiNA Therapeutics
• Ensoma, Inc.
• Reforgene Medicine
• YolTech
• Incisive Genetics
• GluBio Therapeutics
• Enlaza Therapeutics
• Vertex Pharmaceuticals

Key Products

• Etavopivat
• SIL-8301
• Nulabeglogene autogedtemcel
• ITU512
• CS-206
• DISC-3405
• CSL324
• Rilzabrutinib
• BMS-986470
• BEAM-101
• MTL-HBG
• Research Program
• RM001
• YOLT-204
• IG-SCD 1
• GLB-005
• Research Program: Drug Conjugates